Inflammation Clinical Trial
Official title:
The Effect of Ibuprofen on the Endocrine and Metabolic Status of Women With PCOS.
Polycystic ovary syndrome occurs in about 10% of women of childbearing age. His pathogenesis is not fully understood. More and more research concerns the role of chronic inflammation in these women as the cause of the disease. In vitro studies have shown a significant reduction in testosterone production by teak cells after ibuprofen. The goal of the project is to use a low dose of ibuprofen in women with PCOS to lower androgen levels.
Polycystic ovary syndrome 1 is diagnosed in about 4-8% of women of childbearing age and
is,therefore one of the most common endocrinopathies. The exact pathogenetic mechanism of
PCOS is not fully discovered. Some women with PCOS have elevated levels of lutropin, which is
considered to be the strongest stimulator of androgen production in ovarian theca cells. A
breakthrough finding was the causal relationship between insulin resistance and
hyperinsulinemia and hyperandrogenism in patients with PCOS. Confirmation of the theory that
hyperinsulinemia is the cause of hyperandrogenism in these women gave the opportunity to
treat women with PCOS by improving insulin sensitivity. The compartment of ovarian
theca-interstitial cells is responsible for androgen overproduction in women with polycystic
ovary syndrome. The cause of PCOS syndrome is seen in various mechanisms leading to the
proliferation of thecal-interstitial cells. Factors that may affect the ovary in this way may
include hyperinsulinemia, an increase in oxidative stress, exponents of generalized
inflammation, and various cytokines such as TNF-alpha.
Prospective studies performed on women with polycystic ovary syndrome during perimenopause
showed an increased incidence of type II diabetes, hypertension, ischemic heart disease, and
myocardial infarction compared to the control group. In patients with PCOS, an abnormal,
atherogenic lipid profile was found more often, characterized by increased total cholesterol,
LDL and triglycerides, and decreased HDL fraction. Another risk factor for the development of
cardiovascular disease are disorders in the functioning of vascular endothelial cells. In
women with PCOS, elevated levels of C-reactive protein - a marker of chronic inflammation and
endothelin-1, which are exponents of vascular endothelial disorders, were found. In addition,
the risk of developing cardiovascular disease in women with PCOS is increased by elevated
oxidative stress markers. Cardiometabolic diseases have been shown to be associated with
abnormal vascular endothelial function and chronic inflammation. One of the most important
and common indicators of inflammation is abnormally high levels of CRP. The acute phase
protein is produced by hepatocytes due to stimulation by proinflammatory cytokines such as
interleukin-6 (IL-6) and tumor necrosis factor (TNFα). Increased high sensitivity CRP
(hs-CRP) is considered to be one of the most important predictors of the risk of
cardiovascular events. In addition to C-reactive protein, inflammatory cytokines and
chemokines, including IL-18, monocyte-1 chemotactic protein (MCP-1) and macrophage-1a
inflammatory protein (MIP-1a) play an important role in chronic inflammation. Interleukin-18
appears to be associated with insulin resistance and metabolic syndrome and has prognostic
value for cardiovascular death. An increased C-reactive protein concentration was found in
the group of women with PCOS. In 2011, the latest meta-analysis confirming the increased
concentration of hsCRP was presented. Increased IL-18 levels were observed in women with
polycystic ovary syndrome, which correlated with obesity and total testosterone levels.
Individual studies have also shown an increase in the concentration of monocyte-1 chemotactic
protein (MCP-1) in these women. In 2005, Orio et al. Showed a significantly elevated white
blood cell (WBC) concentration in a group of 150 women with PCOS. Oxidative stress and
chronic inflammation are closely related and form a vicious circle concept in which
inflammation generates reactive oxygen species (ROS), while oxidative stress promotes and
exacerbates inflammation. The first report documenting increased oxidative stress in women
with PCOS was published in 2001 by Sabuncu. It was assessed by lipid peroxidation, which was
significantly higher in PCOS and positively correlated with BMI, insulin concentration and
blood pressure. In reference to these risks for women with PCOS - last, the latest and most
arousing emotions pathogenetic theory this team is chronic inflammation probably caused by
the improper composition of bacterial microflora microbiota. However, there are many
undiscovered interrelationship mechanisms between inflammation and endocrine disorders. One
of the theories may be the role of lipopolysaccharide (LPS) released from Gram (-) bacteria
and adversely affecting metabolic functions, and above all insulin resistance. In 2012, a
paper was published in which a correlation between LPS binding protein and metabolic syndrome
and inflammatory markers was demonstrated. The second hypothesis is the induction of chronic
inflammation through specific pathogens. Microorganisms such as Chlamydia pneumoniae and
Helicobacter pylori are associated with chronic inflammation and cardiovascular disease. In
particular, Chlamydia pneumoniae infection correlates with the presence of atherosclerosis
and even acute myocardial infarction, and chronic inflammatory processes associated with
periodontal disease are associated with cardiovascular risk. The theory of specific
microorganisms probably remains the most controversial and least studied concept between PCOS
and chronic infection. Morin-Papunen et al. Observed a higher amount of IgG Chlamydia
pneumonia and Chlamydia trachomatis and hsCRP in women with no ovulation and hirsutism than
in the control group. In another study, the amount of Helico-bacterial pylori was more common
in women with PCOS than in the age-matched control group. In 2011, Dursun published a paper
on periodontal infection in women with PCOS compared to a control group of the same age and
comparable body weight.
The new hypothesis for the treatment of polycystic ovarian syndrome is based on the
assumption that ibuprofen inhibits the proliferation of ovarian theca-intestinal cells,
lowers streroidogenesis, and additionally has a positive effect on insulin and reduces
oxidative stress. Ibuprofen is a medicament from the group of NSAID used for the purpose of
reducing the state zap a cast and analgesic dosage depends on the indication and the
patient's condition. For non-prescription oral ibuprofen, the maximum daily dose is 1.2 g and
has a good safety profile. Under the supervision of a physician and on his behalf, in some
indications, higher doses are used, even up to 3.2 g per day. Low risk of gastrointestinal,
hepatorenal and other complications has been demonstrated. Some, but not all, studies show a
slightly increased cardiovascular risk, but in general, all complications occur less
frequently than when using diclofenac or coxib. Ibuprofen in over-the-counter doses has a low
risk of serious gastrointestinal (GI) complications and the development of kidney problems
and heart disease. Irreversible liver damage is not observed in patients using it, as it
sometimes occurs in patients using paracetamol or aspirin.
The use of ibuprofen in women with PCOS may improve the endocrine and metabolic profile which
may reduce the risk associated with cardiovascular disease
The mechanisms of action of ibuprofen that gave rise to use in the treatment of PCOS are as
follows :
In vitro Ibuprofen inhibits the genes that regulate androgen production ( CYP11 , CYP17 and
HSD ) Ibuprofen inhibits the expression of key genes regulating androgen synthesis by IL-1β
and LPS Ibuprofen attenuates the stimulating effect of IL-1β on the growth of theca cells
Project goals A. Assessment of the effect of ibuprofen on the endocrine and metabolic profile
in women with PCOS B. The effect of ibuprofen on chronic inflammation in women with PCOS
C Recruitment of the patients for testing is scheduled for a period of one year. Will be
based on the classification of patients into three-week application of the ibuprofen, and
assessing the effects of the use of this drug in the daw which 8 00 mg/day ( 2 x 4 00mg) for
3 weeks in women with a bodyweight <70 kg, and a dose of 1200 mg/day (3x400mg) in women
weighing> 70kg. The effects of treatment will be compared on the basis of changes in the
hormonal profile and inflammatory markers, as well as the clinical assessment of the patient.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03995979 -
Inflammation and Protein Restriction
|
N/A | |
Completed |
NCT03255187 -
Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT03577223 -
Egg Effects on the Immunomodulatory Properties of HDL
|
N/A | |
Completed |
NCT04383561 -
Relationship Between LRG and Periodontal Disease
|
N/A | |
Active, not recruiting |
NCT03622632 -
Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
|
||
Completed |
NCT06216015 -
Exercise Training and Kidney Transplantation
|
N/A | |
Completed |
NCT04856748 -
Nomogram to Diagnose Prostatic Inflammation (PIN) in Men With Lower Urinary Tract Symptoms
|
||
Completed |
NCT05529693 -
Efficacy of a Probiotic Strain on Level of Markers of Inflammation in an Elderly Population
|
N/A | |
Recruiting |
NCT05670301 -
Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases
|
N/A | |
Recruiting |
NCT05415397 -
Treating Immuno-metabolic Depression With Anti-inflammatory Drugs
|
Phase 3 | |
Recruiting |
NCT04543877 -
WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study
|
Early Phase 1 | |
Recruiting |
NCT05775731 -
Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
|
||
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Completed |
NCT03429920 -
Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors
|
N/A | |
Completed |
NCT06065241 -
Quantifiably Determine if the Botanical Formulation, LLP-01, Has a Significant Clinical Effect on Proteomic Inflammatory Biomarkers and Epigenetic Changes in Healthy, Older Individuals.
|
N/A | |
Completed |
NCT05864352 -
The Role of Dietary Titanium Dioxide on the Human Gut Microbiome and Health
|
||
Completed |
NCT03318731 -
Efficacy and Safety of Fenugreek Extract on Markers of Muscle Damage and Inflammation in Untrained Males
|
N/A | |
Not yet recruiting |
NCT06134076 -
Comparing Effects of Fermented and Unfermented Pulses and Gut Microbiota
|
N/A | |
Not yet recruiting |
NCT06159543 -
The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes
|
N/A |